We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App

Blood Test Shows Worsening Disability in MS Patients 1 to 2 Years before Occurrence

By LabMedica International staff writers
Posted on 07 Nov 2023
Print article
Image: MS patients whose blood tests reveal elevated NfL could see worsening disability one to two years later (Photo courtesy of 123RF)
Image: MS patients whose blood tests reveal elevated NfL could see worsening disability one to two years later (Photo courtesy of 123RF)

Globally, multiple sclerosis (MS) affects millions of individuals. In its more severe stages, it can significantly impair movement and cause muscle stiffness, diminished strength, coordination issues, and loss of bladder control. However recent developments indicate that these intense symptoms can be significantly postponed or possibly prevented. Now, a new study has revealed that MS patients with higher levels of NfL, a marker indicating nerve cell damage in the blood, could face worsening disability within the following one to two years.

The study led by researchers at University of California San Francisco (San Francisco, CA, USA) is the first to measure the period before there is a notable decline in ability, during which damage to the brain and spinal cord occurs in MS patients. The researchers examined the incidence of increased disability, defined as six months or more of rising impairment reflected in a higher score on the Expanded Disability Status Scale. They distinguished between the worsening of disability associated with a relapse—characterized by lingering symptoms or the resurgence of previous ones—and the steady advancement of symptoms without a relapse.

In their analysis, the team examined data spanning more than a decade from around 4,000 visits by patients to UCSF, part of the EPIC study, and roughly 9,000 visits from multiple locations in Switzerland, as part of the SMSC study. These studies encompassed close to 1,900 individuals. Out of these, 570 patients were identified as having progressively worsening disability, with the larger number experiencing this independent of relapses. The findings linked high NfL levels with an up to 91% increased likelihood of disability that intensified with a relapse about a year later, and an up to 49% increased likelihood of disability progression without a relapse nearly two years later. The researchers are now focusing on future research to identify treatments that can halt this progression during the time when NfL levels are elevated.

“In addition to the groundbreaking findings on the temporal relationship between NfL increases and gradual disease progression in MS, the study supports the important role of NfL as an early marker of nerve damage,” said Jens Kuhle, MD, PhD. “Monitoring NfL levels might be able to detect disease activity with higher sensitivity than clinical exam or conventional imaging.”

Related Links:
UC San Francisco

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more


view channel
Image: The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) (Photo courtesy of HORIBA)

New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds

HORIBA (Kyoto, Japan) has expanded its line of compact hematology analyzers by introducing new models that incorporate Erythrocyte Sedimentation Rate (ESR) measurement capabilities. The newly launched... Read more


view channel
Image: High-speed brightfield scanners offer excellent image quality to aid pathologists\' review of digital slides (Photo courtesy of Roche)

Whole-Slide Imaging System Enables Pathologists to Diagnose Patients Using Digital Images

Digital pathology involves the digitalization of the traditional pathology workflow, starting from slide scanning to visualization, to analysis. Digital pathology is transforming traditional histopathology... Read more


view channel
Image: The global urinalysis market is projected to grow at a CAGR of 9.6% to USD 6.8 billion by 2029 (Photo courtesy of Shutterstock)

Global Urinalysis Market Driven by Technological Advancements in POC Testing

Urinalysis is a practical and efficient technique for analyzing urine samples to detect various infections and chronic diseases such as diabetes, urinary tract infections, and kidney disease.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.